The low-density lipoprotein receptor (LDLR) pulls cholesterol-carrying LDL particles out of the bloodstream and into liver cells for clearance. Most people know that rare LDLR mutations cause familial hypercholesterolemia, a severe inherited condition of massively elevated cholesterol. But LDLR is also shaped by a network of common regulatory variants that subtly tune how much functional receptor your liver produces — variants that don't alter the protein sequence at all, yet still affect cholesterol levels measurably.

rs5925 is one such variant. Located in exon 13 of LDLR, it produces a synonymous change (c.1959T>C, p.Val653=): both alleles encode valine, so the protein sequence is identical regardless of which allele you carry. Yet [multiple population studies across Chilean, Egyptian, South Indian, and Chinese cohorts | Rojas 2019; Alsabbagh 2022; Jha 2019; Wang 2023] have associated the C allele with higher LDL cholesterol and cardiovascular risk. The molecular explanation involves mRNA splicing — a key step in gene regulation that occurs after transcription but before the protein is made.

The Mechanism

Synonymous variants can profoundly affect gene output by disrupting exonic splicing enhancers (ESEs)¹¹ exonic splicing enhancers (ESEs)
Short RNA sequences within exons that signal to the spliceosome to include the exon in the mature mRNA. If an ESE is disrupted, the spliceosome may skip the exon, producing a truncated or non-functional protein.

The Lee et al. 2014 minigene study²² Lee et al. 2014 minigene study
Lee JD et al. Mutual effect of rs688 and rs5925 in regulating low-density lipoprotein receptor splicing. DNA Cell Biol, 2014 demonstrated that rs5925 and the nearby synonymous variant rs688 (exon 12) jointly control LDLR exon splicing efficiency. Using minigene constructs in human cell lines and confirmed in leukocyte RNA from patients, they measured how efficiently exon 12 and exon 13 were retained in mature LDLR mRNA across all four possible haplotype combinations:

• rs688-C / rs5925-C: 79.6% splicing efficiency (highest)
• rs688-C / rs5925-T: 76.7%
• rs688-T / rs5925-C: 69.0%
• rs688-T / rs5925-T: 68.5% (lowest)

rs5925 accounts for approximately 5.4% of splicing efficiency difference when rs688 carries the C allele. Critically, rs688-T (itself associated with reduced exon 12 inclusion) and rs5925-C rarely co-occur in high-splicing haplotypes in the populations where C-allele LDL elevation is observed — the predominant clinical haplotype combines rs688-T with rs5925-C, creating the TC combination with 69% efficiency versus the protective CC combination at 79.6%. This haplotype context explains why the population-level C allele effect on LDL is adverse despite rs5925-C appearing more efficient when paired with rs688-C.

The Evidence

Clinical evidence from multiple independent cohorts consistently links the C allele with higher LDL cholesterol. In a study of 178 healthy subjects from northern Chile³³ study of 178 healthy subjects from northern Chile
Rojas C et al. JCLA, 2019, individuals carrying at least one T allele had significantly lower total cholesterol, triglycerides, and LDL-C than CC homozygotes (p<0.05). The distribution in this Latin American population (CC 19%, CT 53%, TT 28%) closely matches Hardy-Weinberg predictions for a C allele frequency of ~45-53%, consistent with global gnomAD data.

In a case-control study of 400 South Indians⁴⁴ case-control study of 400 South Indians
Jha CK et al. Med Sci, 2019 (200 coronary artery disease patients, 200 matched controls), the heterozygous genotype at rs5925 was significantly protective against CAD (OR=0.45, 95% CI 0.27-0.75, p=0.002), demonstrating that the T allele confers cardiovascular protection beyond lipid levels alone.

An Egyptian study of 100 lupus nephritis patients⁵⁵ Egyptian study of 100 lupus nephritis patients
Alsabbagh YA et al. Arch Rheumatol, 2022 found the C allele significantly more prevalent in patients than healthy controls (60% vs 45%, p=0.003), with CC genotype carriers showing higher atherogenic index and LDL/HDL ratios. TT and CT genotypes showed significantly lower TC, TG, and LDL-C than CC homozygotes.

A 2023 Chinese adolescent study⁶⁶ 2023 Chinese adolescent study
Wang J et al. Int J Mol Sci, 2023 involving 709 students confirmed that male C allele carriers had elevated total cholesterol and LDL-C compared to TT homozygotes in the control group.

Notably, one Chilean pharmacogenomics study⁷⁷ Chilean pharmacogenomics study
Lagos J et al. Int J Mol Sci, 2015 examining atorvastatin response in 139 hypercholesterolemic subjects found no significant association between rs5925 and statin-induced LDL reduction (p=0.576). This suggests the variant's effect on LDLR expression levels does not meaningfully alter the pharmacodynamic response to statins, which primarily works through a separate mechanism (inhibiting cholesterol synthesis and upregulating LDLR protein quantity rather than splicing efficiency).

Practical Actions

For CC homozygotes, the elevated LDL risk is modest in absolute terms — this is not a pathogenic variant, and the LDL difference between genotypes is in the range of a few mg/dL to perhaps 10-15 mg/dL in studies with the largest effects. The practical implication is attentiveness: more frequent LDL monitoring, prompt action when cholesterol trends upward, and consideration of dietary and pharmaceutical interventions earlier rather than later.

Dietary strategies with the strongest LDL-lowering evidence independent of genotype — soluble fiber, plant sterols, reduced saturated fat — are particularly relevant for CC carriers since their genetic baseline LDLR efficiency is lower. These interventions enhance cholesterol clearance through mechanisms that can partially compensate for reduced splicing efficiency.

Because statin response does not appear to track with rs5925 genotype, standard lipid management guidelines apply to CC homozygotes who require pharmacotherapy.

Interactions

rs5925 functions within a two-SNP regulatory module with rs688. The splicing efficiency of LDLR exon transcripts is jointly determined by both variants, with rs688 being the dominant partner (accounting for ~9.4% vs rs5925's ~5.4% of the variation in splicing efficiency). Together, the rs688-T / rs5925-C haplotype produces the lowest splicing output. Individuals carrying both risk alleles (rs688-T and rs5925-C) have the most reduced LDLR mRNA splicing efficiency and may face compounded LDL-raising effects.

This variant also operates in the context of the broader LDLR regulatory landscape. rs6511720 (intron 1) modulates LDLR transcription through a sterol response element — it affects how much mRNA is produced before splicing even occurs. A CC homozygote at rs5925 who also carries the rs6511720 GG genotype (common, lower-expression) would experience a compounded reduction in functional LDLR output: reduced transcription AND reduced splicing efficiency. Conversely, rs6511720-T carriers (enhanced transcription) may partially offset the splicing inefficiency of the rs5925-C allele by producing more total transcript.

Coagulation factor IX sits at the centre of the intrinsic pathway of blood clotting. When activated by factor XIa, it forms the tenase complex with factor VIIIa, which in turn activates factor X to trigger fibrin clot formation. Severe loss-of-function mutations in F9 cause haemophilia B (Christmas disease). Factor IX Malmö — rs6048, the common p.Thr194Ala missense variant¹¹ p.Thr194Ala missense variant
An amino acid change from threonine to alanine at position 194 of the canonical pre-pro-protein; also reported as Ala148Thr in older literature using mature-protein numbering that excludes the signal peptide and propeptide — is a far subtler story: a common polymorphism that modestly shifts clotting risk in the general population without causing haemophilia.

Because F9 is located on the X chromosome, males carry only one copy (hemizygous), while females can carry zero, one, or two copies of the protective G allele. Genotyping chips typically report hemizygous males as homozygous in the raw data, so a male reported as GG carries exactly one G allele, and a male reported as AA carries one A allele.

The Mechanism

At position 194 in the pre-pro-factor IX sequence, the common A allele encodes threonine; the protective G allele encodes alanine. This substitution is located in the EGF-1 domain of the factor IX protein, a region involved in calcium binding and factor VIIIa interaction. Despite this structurally interesting location, a key finding from the primary association study is that factor IX antigen levels and factor IX activation peptide levels — markers of factor IX production and activation — did not differ significantly between AA and GG carriers²² factor IX antigen levels and factor IX activation peptide levels — markers of factor IX production and activation — did not differ significantly between AA and GG carriers
Bezemer et al. 2009 measured both factor IX antigen and FIXa activation peptide in controls from the LETS (n=191) and MEGA (n=823+484) studies; no significant genotype effect. This means the mechanism of the G allele's protective effect is genuinely unknown — it is not simply producing less factor IX or generating less activated factor IX. Whether the alanine substitution subtly alters factor IX's interaction with factor VIIIa, phospholipid membranes, or inhibitory proteins such as antithrombin remains to be determined.

An adjacent intronic variant (rs422187) showed similar association to DVT in the Bezemer study, raising the possibility that rs6048 may partly or wholly tag a functional non-coding variant in linkage disequilibrium, rather than being the causal change itself.

The Evidence

The key association study is the 2009 analysis by Bezemer and colleagues³³ 2009 analysis by Bezemer and colleagues
Irene D Bezemer et al., "F9 Malmö, factor IX and deep vein thrombosis," Haematologica 2009;94(5):693–9. Combined LETS and MEGA case-control studies with 380+1,469 male cases and factor IX measurements in 191+823+484 controls, which combined two Dutch case-control studies (LETS and MEGA) to demonstrate that the G allele of rs6048 was associated with a 20% reduction in DVT odds: OR 0.80 (95% CI 0.69–0.93). This finding was subsequently replicated in large GWAS datasets. The Klarin 2019 genome-wide association study⁴⁴ genome-wide association study
Derek Klarin et al., "Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease," Nature Genetics 2019;51:1574–1579. Over 650,000 participants across the Million Veteran Program and UK Biobank identified the rs6048-A allele among 33 genomic loci associated with VTE risk (OR ~1.07). The cross-ancestry replication by Thibord et al. 2022⁵⁵ Thibord et al. 2022
Florian Thibord et al., "Cross-Ancestry Investigation of Venous Thromboembolism Genomic Predictors," Circulation 2022;146:1225–1242. 135 VTE loci identified across European, African, and Hispanic cohorts confirmed rs6048 across European, African, and Hispanic populations.

Importantly, a study of VTE recurrence in 2,185 patients⁶⁶ study of VTE recurrence in 2,185 patients
Roach et al. 2015, J Thromb Haemost 2015;13(10):1815–22. Four European cohorts: MEGA, Leiden Thrombophilia Study, Scottish Thrombophilia Study, Vienna Thrombosis Research Group found that Factor IX Malmö did not explain the observed sex difference in VTE recurrence risk. This suggests the variant's modest protective effect applies to first VTE events but does not substantially alter recurrence dynamics.

The effect size is modest — OR ~0.80 for DVT first event — and the clinical significance classification by the ClinGen Coagulation Factor Deficiency Variant Curation Expert Panel (4-star review, February 2024) is benign for haemophilia B and protective for DVT. This is not a variant that eliminates thrombosis risk; it shifts it modestly on a population scale.

Practical Implications

For carriers of the GG genotype (females with two protective alleles) or males with the G allele, the practical implication is limited: a modest downward adjustment in baseline DVT risk. This does not substitute for standard DVT prevention measures during high-risk situations (surgery, prolonged immobility, hormonal contraceptives), particularly if other prothrombotic variants are present (Factor V Leiden, prothrombin G20210A).

For AA homozygotes and AG heterozygotes, no specific intervention is warranted based on this variant alone, since the common A allele simply represents population-average coagulation factor IX function.

The G allele frequency varies dramatically by ancestry — approximately 30% in Europeans and Ashkenazi Jews, 18% in South Asians, 13% in Africans, and less than 0.2% in East Asians. This means the protective variant is essentially absent in East Asian populations, and population-level DVT risk attributable to this locus differs substantially by ancestry.

Interactions

The most clinically relevant interactions are with other coagulation pathway variants. Factor V Leiden (rs6025) and prothrombin G20210A (rs1799963) are the two most common inherited thrombophilias and act at different points in the coagulation cascade. If a carrier of rs6048-G also carries prothrombotic variants, the modest protective effect of the G allele would be expected to partially, but incompletely, offset the elevated risk. The magnitude of this offset has not been directly quantified in published studies.

The adjacent intronic SNP rs422187 is in strong linkage disequilibrium with rs6048 and showed comparable DVT association in the Bezemer cohort. These variants cannot be distinguished functionally with current evidence.

In 2011, a landmark genome-wide association study scanning 61,089 individuals of Caucasian and Asian Indian descent identified an intergenic variant near the HSD17B13 gene on chromosome 4 as one of the strongest signals for plasma ALT concentrations — a key marker of liver injury: Chambers JC et al. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nature Genetics, 2011¹¹ Chambers JC et al. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nature Genetics, 2011. That variant was rs6834314, and its protective G allele was associated with lower liver enzyme levels in the general population. However, subsequent functional work established that rs6834314 itself has no direct effect on HSD17B13 gene expression or enzyme activity. Its associations are entirely a consequence of linkage disequilibrium²² linkage disequilibrium
Two variants are in LD when they co-occur on the same chromosome more often than expected by chance; r² measures how predictively one tags the other with the causal splice variant rs72613567 (D'=0.995, r²=0.93). Knowing your rs6834314 genotype tells you almost exactly what your rs72613567 genotype is — these two variants are nearly perfect proxies for each other.

The Mechanism

rs6834314 is located approximately 11 kb downstream of the HSD17B13 gene in an intergenic region and has no predicted regulatory or coding consequence. The variant's associations with liver disease risk, liver inflammation, and liver enzyme levels are entirely attributable to its co-inheritance with rs72613567, the adenine insertion adjacent to the splice donor site of intron 6³³ adenine insertion adjacent to the splice donor site of intron 6
rs72613567 disrupts the splice donor site, generating an aberrant truncated transcript (isoform D) that encodes a non-functional HSD17B13 protein with reduced enzymatic activity in HSD17B13. This was confirmed by Ma et al. (2019), who showed that rs6834314 genotype was not associated with hepatic HSD17B13 expression levels after accounting for the rs72613567 splice variant.

The Evidence

The clinical signal captured by rs6834314 mirrors the rs72613567 findings precisely, because the two variants tag the same underlying haplotype. In 768 Caucasian patients with biopsy-proven NAFLD, Ma et al. found the rs6834314 G allele (tagging the HSD17B13 loss-of-function haplotype) was associated with lower risk of liver inflammation (OR 0.77), reduced hepatocyte ballooning (OR 0.67), fewer Mallory-Denk bodies (OR 0.68), and lower serum transaminases and GGT. In the general population cohort (Michigan Genomics Initiative), the G allele was associated with a 21% reduction in cirrhosis risk (OR 0.79, p=7.5×10⁻⁴): Ma Y et al. 17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease. Hepatology, 2019⁴⁴ Ma Y et al. 17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease. Hepatology, 2019.

In a multi-ethnic Asian cohort, Seto et al. followed 165 biopsy-proven NAFLD patients for a mean of 89 months and found that each rs6834314 G allele was associated with lower odds of NAFLD (adjusted OR 0.59, 95% CI 0.40–0.87) and NASH (adjusted OR 0.48, 95% CI 0.31–0.75). Homozygous GG individuals showed markedly lower liver-related complication rates during follow-up. However, the protective effect was observed only in ethnic Chinese, not in Malays or Indians within the same cohort — likely reflecting population-specific LD patterns between rs6834314 and the causal rs72613567 insertion: Seto WK et al. Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: results from a multi-ethnic Asian cohort. Clinical and Molecular Hepatology, 2021⁵⁵ Seto WK et al. Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: results from a multi-ethnic Asian cohort. Clinical and Molecular Hepatology, 2021.

In Japanese patients with biopsy-proven NAFLD (n=290), rs6834314 G allele carriage abolished the fibrosis-promoting effect of PNPLA3 I148M: among HSD17B13 AA carriers, PNPLA3 GG conferred significantly higher advanced fibrosis risk (OR 2.4, p=0.041); among HSD17B13 AG/GG carriers, no such PNPLA3 effect was detected. The G allele was also associated with lower inflammation and ballooning prevalence: Seko Y et al. Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease. Liver International, 2020⁶⁶ Seko Y et al. Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease. Liver International, 2020.

Practical Implications

The clinical interpretation of rs6834314 is structurally identical to that of rs72613567, because they tag the same biological state. If your genome file includes rs6834314 but not rs72613567 (a scenario most likely on older Illumina arrays that predated specific addition of the HSD17B13 locus), your rs6834314 genotype tells you the same information: whether you carry the HSD17B13 loss-of-function haplotype. The G allele protective association with liver inflammation and fibrosis is real — it just originates from a functionally upstream cause.

One important caveat specific to rs6834314: because protection depends on LD, and LD patterns can differ between ancestral populations, the G allele is a reliable proxy for rs72613567 in European and East Asian populations (r²=0.93) but may be a less accurate proxy in other ancestries, particularly in populations not well-represented in the original LD reference panels.

Interactions

The most clinically important interaction is between the HSD17B13 loss-of-function haplotype (tagged by rs6834314 G) and PNPLA3 rs738409 (I148M). The high-risk PNPLA3 GG genotype strongly predicts advanced fibrosis in HSD17B13 AA carriers but not in G allele carriers — meaning the HSD17B13 protective haplotype functionally overrides much of the PNPLA3 fibrosis risk. This same interaction was originally described for rs72613567 in the Abul-Husn NEJM 2018 cohort and replicated here using rs6834314 as the proxy.

See also rs58542926 (TM6SF2 E167K), which operates in the same hepatic lipid droplet biology axis and further stratifies liver disease risk when combined with PNPLA3 and HSD17B13 genotypes.

Your skin makes vitamin D through a two-step process: ultraviolet B light converts 7-dehydrocholesterol (7-DHC)¹¹ 7-dehydrocholesterol (7-DHC)
A cholesterol precursor concentrated in the outer skin layers. It is the substrate for both vitamin D synthesis and DHCR7-mediated cholesterol production in the outer skin into previtamin D3, which spontaneously rearranges into vitamin D3 (cholecalciferol). But the same 7-DHC molecule is also the substrate for DHCR7 (7-dehydrocholesterol reductase), the enzyme that converts it into cholesterol — making DHCR7 a molecular switch governing how much sunlight exposure translates into vitamin D.

rs7944926 is an intronic variant in the NADSYN1 gene on chromosome 11, situated within the same large haplotype block²² haplotype block
A segment of DNA inherited as a unit, typically because recombination within the block is rare. SNPs within a haplotype block track together through generations as the canonical DHCR7 vitamin D variant rs12785878, spanning 63–102 kb depending on the population. The two variants are in near-perfect linkage disequilibrium³³ linkage disequilibrium
LD measures how strongly two variants travel together in a population. r² ≈ 1.0 means the two SNPs are essentially interchangeable as genetic proxies for each other (r² ≈ 1.0 in Europeans), meaning rs7944926 tags exactly the same biological signal as rs12785878. The A allele at rs7944926 co-segregates with the G allele at rs12785878 — both associated with lower circulating 25-hydroxyvitamin D.

The Mechanism

The functional effect at this locus is attributed to regulatory changes that alter DHCR7 transcription or activity. Higher DHCR7 activity channels more 7-DHC toward cholesterol synthesis via the Kandutsch-Russell pathway⁴⁴ Kandutsch-Russell pathway
One of two routes for cellular cholesterol synthesis. DHCR7 reduces the C7-8 double bond in 7-DHC using NADPH, producing cholesterol on the smooth endoplasmic reticulum, leaving less 7-DHC available for UV-driven vitamin D synthesis in the skin. Cholesterol itself accelerates the proteasomal degradation of DHCR7 protein, creating a feedback loop: when cholesterol is plentiful, DHCR7 degrades, 7-DHC accumulates, and vitamin D production is favored. Risk-allele carriers appear to disrupt this balance, sustaining higher DHCR7 activity and reducing vitamin D synthesis capacity.

The Evidence

The landmark 2010 Lancet GWAS⁵⁵ landmark 2010 Lancet GWAS
Wang TJ et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet, 2010 in 33,996 Europeans identified the DHCR7/NADSYN1 locus as one of three genome-wide significant loci for 25(OH)D concentration (P = 2.1 × 10⁻²⁷). Carriers of two risk alleles had mean 25(OH)D approximately 8 nmol/L lower than non-carriers under the same conditions. Each additional risk allele increased the odds of vitamin D insufficiency (below 75 nmol/L) by about 21%.

An evolutionary genetics study⁶⁶ evolutionary genetics study
Kuan V et al. DHCR7 mutations linked to higher vitamin D status allowed early human migration to northern latitudes. BMC Evol Biol, 2013 demonstrated that rs7944926 specifically showed signatures of strong positive selection in European and East Asian populations, with FST values⁷⁷ FST values
FST measures allele frequency differentiation between populations. Values above the 95th percentile relative to genome-wide SNPs indicate selection pressures, not just genetic drift above the 95th percentile on chromosome 11. The G allele (protective, higher vitamin D) rose dramatically in frequency at northern latitudes — from ~15–16% in sub-Saharan Africa to ~72% in Europeans — consistent with selection pressure to maintain vitamin D synthesis in low-UVB environments. This population differentiation is among the strongest seen anywhere in the human genome for this region.

The findings have been confirmed in massive replication. A UK Biobank GWAS⁸⁸ UK Biobank GWAS
Manousaki D et al. Genome-wide association study for vitamin D levels reveals 69 independent loci. Am J Hum Genet, 2020 in 401,460 participants and a concurrent 143-loci study⁹⁹ 143-loci study
Revez JA et al. Genome-wide association study identifies 143 loci associated with 25 hydroxyvitamin D concentration. Nat Commun, 2020 in 417,580 Europeans both confirmed DHCR7/NADSYN1 among the strongest vitamin D loci. rs7944926 has been used as a direct instrument in Mendelian randomization studies of vitamin D-disease relationships, with each A allele associated with approximately 2–3 nmol/L lower serum 25(OH)D.

Practical Implications

Because rs7944926 is an LD proxy for rs12785878, its clinical meaning is identical to that of its canonical partner: a genetic tendency toward reduced vitamin D3 synthesis from sunlight. The per-allele effect is modest in isolation, but it compounds with other vitamin D pathway variants (CYP2R1 rs10741657 for hepatic hydroxylation, GC rs2282679 for D-binding protein transport, CYP24A1 rs6013897 for active D degradation), limited sun exposure, higher latitude, and darker skin pigmentation.

The A allele does not impair absorption of dietary or supplemental vitamin D, making supplementation an effective countermeasure.

Array Coverage Note

This SNP is included in the GeneOps database as an array coverage proxy. If your genome file includes rs12785878 directly, that entry provides equivalent information. If rs12785878 was not genotyped on your array, rs7944926 captures the same biological signal. Both cannot give discordant results in a person with a high-quality genome file — if both are present, results should be consistent.

Evolutionary Context

The stark frequency gradient of the G (protective) allele — from ~12% in West African populations to ~72% in Europeans and ~42% in East Asians — is one of the clearest signatures of latitude-driven natural selection in the human genome. As populations migrated from equatorial Africa to regions with weaker UV radiation, variants that redirected more 7-DHC toward vitamin D synthesis conferred survival advantages against rickets, immune dysfunction, and reproductive impairment. rs7944926 marks this same adaptive sweep.

Interactions

rs7944926 is functionally equivalent to rs12785878 and participates in the same four-locus vitamin D pathway network. Wang et al. (2010) found that individuals in the highest quartile of a combined genetic risk score across DHCR7, CYP2R1 (rs10741657), GC (rs2282679), and CYP24A1 (rs6013897) had 2.47 times the odds of vitamin D insufficiency compared to the lowest quartile. If you carry risk alleles at multiple loci, compound vitamin D supplementation guidance is warranted.

At the growing tip of every microtubule in a dividing cell sits a small protein called EB1, encoded by MAPRE1. Its job is deceptively simple: ride the plus ends of microtubules and recruit the molecular machinery that keeps the spindle — the apparatus responsible for separating chromosomes — working properly. When EB1 fails to do this job correctly during oocyte meiosis, chromosomes can missegregate, producing aneuploid eggs that either fail to fertilize or result in miscarriage. The rs853854 variant in MAPRE1 marks a locus that a major European GWAS meta-analysis linked to polycystic ovary syndrome susceptibility, connecting a cell-biology workhorse to one of the most common causes of female reproductive difficulty.

The Mechanism

MAPRE1 encodes EB1¹¹ EB1
end-binding protein 1; a plus-end tracking (+TIP) protein that localizes to the growing tips of microtubules throughout the cell cycle. EB1 acts as a master regulator of the +TIP network, recruiting downstream effectors to microtubule ends and promoting spindle assembly. rs853854 is an intronic variant at the MAPRE1 locus on chromosome 20q11.21 — it does not change the EB1 protein directly, but tags regulatory variation that likely influences MAPRE1 expression levels or splicing in relevant tissues.

Single-cell eQTL analysis in immune cells has identified MAPRE1 as a causal PCOS gene with regulatory effects in NK cells; the risk-associated haplotype correlates with reduced MAPRE1 expression in these cells, suggesting broader immune and ovarian effects beyond the classical androgen excess pathway.

The link to oocyte biology is direct. Zhou et al. 2021²² Zhou et al. 2021
EB1 Is Essential for Spindle Formation and Chromosome Alignment During Oocyte Meiotic Maturation in Mice. Microsc Microanal 27:385–391 showed that EB1 protein localizes along the meiotic spindle, mirroring α-tubulin distribution. When EB1 was depleted using a Trim-Away approach, the consequences were severe: spindle disorganization, chromosome misalignment and missegregation, reduced conversion to mature MII oocytes, and decreased β-catenin at the cortical adherens junctional complex. The impairment of EB1 function promotes chromosomal loss — fuelling aneuploidy and potential fertilization failure.

The Evidence

Day et al. 2018³³ Day et al. 2018
Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. PLoS Genet 14:e1007813 is the primary source of evidence for this variant. The study combined 10,074 PCOS cases and 103,164 controls of European ancestry in a fixed-effect inverse-variance-weighted meta-analysis, identifying 14 genome-wide significant PCOS susceptibility loci. The rs853854 locus near MAPRE1 was among three novel associations discovered, the others being near PLGRKT and ZBTB16. The authors characterized MAPRE1 as a metabolic candidate gene that interacts with LRP1 — a receptor that controls adipogenesis — and may additionally mediate ovarian angiogenesis and follicle development.

This variant has not yet been replicated at genome-wide significance in independent cohorts of comparable power, and no specific functional variant within the locus has been causally validated. The evidence level is therefore moderate: replicated within the European GWAS framework, biologically plausible via EB1's established spindle role, but lacking the cross-ethnic replication and molecular fine-mapping of more established PCOS loci like DENND1A or FSHR.

The allele frequency differs strikingly by ancestry: the T risk allele reaches 50% in Europeans but only 9% in East Asians and 16% in Africans. This suggests the variant, or a closely linked causal variant, may have experienced different selection pressures across populations.

Practical Actions

Because the MAPRE1 locus influences PCOS risk through a pathway that includes ovarian angiogenesis and potentially oocyte spindle stability, women with the T risk allele who are planning to conceive — or who are undergoing fertility treatment — have actionable considerations. Spindle stability during oocyte maturation is sensitive to oxidative stress and mitochondrial function; coenzyme Q10 supplementation has evidence for improving spindle integrity in eggs under oxidative stress. Anti-Müllerian hormone (AMH) testing combined with antral follicle count assesses the ovarian reserve and follicular health most directly affected by PCOS-related follicular arrest.

The MAPRE1 locus does not operate through the androgen excess pathway that dominates DENND1A-associated PCOS. Women carrying the rs853854 T allele alongside a normal androgen profile should not assume they are protected from PCOS-related reproductive difficulty — the MAPRE1 mechanism likely acts independently through follicular development and potential oocyte quality.

Interactions

The three novel loci identified in Day 2018 — MAPRE1, PLGRKT, and ZBTB16 — likely operate through mechanisms partly distinct from the earlier Chinese GWAS loci (DENND1A, THADA, FSHR/LHCGR). Carrying risk alleles at both MAPRE1 (rs853854) and DENND1A (rs7852296) would represent additive burden from two different PCOS pathways: spindle/follicular development (MAPRE1) and androgen excess/FSH resistance (DENND1A). No published compound effect size exists for this combination, but the biological mechanisms are sufficiently distinct that the combined phenotype may be more complex than either alone.

Every cell in your body carries the same DNA sequence, yet a liver cell and a neuron behave completely differently. That feat of biological differentiation depends on DNA methylation — the chemical tagging of cytosines ¹¹ Cytosines are one of the four DNA bases; methylation adds a methyl group (–CH₃) to position 5, creating 5-methylcytosine without changing the underlying sequence that silences or activates genes without altering the underlying code. DNMT3A (DNA methyltransferase 3 alpha) is one of the primary enzymes that writes these methyl tags during development and throughout adult life. Variants in DNMT3A alter how efficiently — and where — this enzyme deposits methylation marks, with downstream effects on gene expression, stress-response circuits, and immune cell balance.

The Mechanism

rs11683424 is an intronic variant in DNMT3A, located on chromosome 2 (GRCh38: 25,266,262). Intronic variants can alter ²² Introns are non-coding stretches within genes; variants here can change mRNA splicing, alter regulatory elements, or affect transcript levels without changing the protein sequence pre-mRNA splicing, disrupt internal regulatory elements such as intronic enhancers, or influence transcript stability — all without changing the amino acid sequence of the DNMT3A protein. The exact molecular mechanism for rs11683424 has not been characterized in published literature, but the functional associations documented — altered stress-response gene regulation and shifts in immune cell ratios — are consistent with subtle, tissue-specific changes in DNMT3A expression or isoform balance.

DNMT3A works by de novo methylation: it places methyl marks on previously unmethylated cytosines, primarily in the context of early development, neuronal differentiation, and immune cell programming. In the brain, DNMT3A is expressed in neurons and glia, where it helps establish methylation patterns at genes governing synaptic plasticity and stress-response pathways. In the bone marrow, DNMT3A is essential for normal hematopoietic stem cell differentiation — which explains why somatic DNMT3A mutations are among the most common drivers of clonal hematopoiesis and acute myeloid leukemia, though those are distinct from the germline variant rs11683424.

The Evidence

The stress-modulation evidence for rs11683424 centers on a multi-sample gene-environment interaction study³³ multi-sample gene-environment interaction study
Pishva E et al. Epigenetic genes and emotional reactivity to daily life events. PLoS One, 2014 across 867 participants spanning healthy volunteers, population controls, and psychiatric patients. The T allele consistently buffered the effect of daily stressors on negative affect — carriers reported reduced emotional reactivity to adverse events across three of five independent cohorts. This buffering effect is biologically plausible: DNMT3A is expressed in stress-relevant brain regions, and altered methylation at glucocorticoid-response genes could attenuate the stress axis.

A second cross-sectional study⁴⁴ cross-sectional study
Barliana MI et al. DNA methyltransferase 3A gene polymorphism contributes to daily life stress susceptibility. Psychol Res Behav Manag, 2017 in 129 healthy Indonesian adults (genotype distribution: CC 14%, CT 81%, TT 5%) found that DNMT3A rs11683424 genotype significantly associated with daily life stress susceptibility (p=0.04). Subjects with the CT genotype were the most frequently classified under stress conditions. This finding is somewhat at odds with the buffering narrative from Pishva 2014 — the two studies differ in population, stress measurement (daily stress scales vs ecological momentary assessment), and direction of effect framing, highlighting the need for caution in interpreting early-stage evidence.

From a different angle, a large GWAS in childhood leukemia⁵⁵ GWAS in childhood leukemia
Kachuri L et al. Genetic determinants of blood-cell traits influence susceptibility to childhood acute lymphoblastic leukemia. Am J Hum Genet, 2021 identified rs11683424 as a genome-wide significant locus for neutrophil-to-lymphocyte ratio (NLR; p=1×10⁻¹¹), with the C allele associated with higher NLR. NLR is an epigenetically regulated immune metric, and the association underscores that DNMT3A variants influence immune cell differentiation in vivo. Higher NLR reflects a relative neutrophil predominance and is often used as an inflammatory marker.

A large case-control study⁶⁶ large case-control study
Berking AC et al. DNMT3A and 3B variability and panic disorder. J Neural Transm, 2020 in 3,618 individuals found no major association between DNMT3A variants and panic disorder, though minor protective signals emerged for anxiety dimensions in healthy controls — consistent with the possibility of small, context-dependent effects.

Practical Actions

The actionable implications of rs11683424 center on supporting DNMT3A enzyme function through adequate methyl-donor supply. DNMT3A requires SAM (S-adenosylmethionine) as its methyl-group donor. SAM is synthesized from methionine and is directly sustained by the one-carbon / methylation cycle — the same pathway fed by folate, B12, B6, and betaine. If this pathway is constrained (e.g., by co-occurring MTHFR variants), DNMT3A activity can be limited by substrate availability, potentially amplifying whatever expression shift rs11683424 imparts.

For T allele carriers interested in stress modulation, the evidence from Pishva 2014 suggests the T allele itself may already buffer emotional stress reactivity — which is not necessarily a disadvantage. The CT and TT genotypes should focus on supporting the methylation substrate pool and monitoring stress-response biomarkers over time.

Interactions

The most relevant interaction is with MTHFR C677T (rs1801133). MTHFR reduces the supply of 5-methylTHF, which is upstream of homocysteine remethylation to methionine, the precursor of SAM. Individuals carrying both reduced-function MTHFR and the DNMT3A rs11683424 T allele face a potential dual constraint: reduced SAM availability plus altered DNMT3A expression. MTRR rs1801394 also participates in methionine regeneration and would compound any SAM limitation.

The DNMT3A rs1465764 variant (also in the same gene) was examined alongside rs11683424 in the Pishva 2014 study, and both moderated stress-response negative affect, suggesting that multiple regulatory variants in DNMT3A may act in concert.

This is the second most-studied variant in the TCF7L2 gene, located in intron 4 approximately 50 kb from the primary variant rs7903146. While rs7903146 is the primary diabetes risk variant, rs12255372 provides additional information about your TCF7L2 haplotype. The two variants are in moderate linkage disequilibrium¹¹ Linkage disequilibrium means these variants tend to be inherited together because they sit close on the same chromosome, within a 92-kb LD block, meaning they are often co-inherited but not always.

The Mechanism

Like rs7903146, this variant sits in a non-coding region and is thought to influence TCF7L2 expression levels, though rs7903146 appears to be the stronger functional driver. The T allele at this position is associated with decreased insulin secretion and impaired incretin response.

The Evidence

A meta-analysis of 28 studies²² meta-analysis of 28 studies
Wang et al. Association of rs12255372 in the TCF7L2 gene with type 2 diabetes mellitus: a meta-analysis. Braz J Med Biol Res, 2013 confirmed the association with type 2 diabetes with an odds ratio of 1.39 (95% CI: 1.35-1.42). The effect is consistent across European, African, and South Asian populations but weaker in East Asian populations where the T allele is rare (~2% frequency).

The Pounds Lost trial³³ Pounds Lost trial
Mattei et al. Am J Clin Nutr, 2012 also examined rs12255372 and found that T allele carriers who consumed a lower-fat diet had greater reductions in body adiposity, which could improve glycemic control.

Practical Implications

Having risk alleles at both rs7903146 and rs12255372 compounds your overall TCF7L2-related diabetes risk. The dietary recommendations are the same: moderate fat intake and a Mediterranean-style eating pattern.

Interactions

This variant is in moderate linkage disequilibrium with rs7903146. If you carry risk alleles at both positions, your overall TCF7L2-related risk is higher.

Interleukin-33¹¹ Interleukin-33
IL-33 is an alarmin cytokine constitutively expressed in the nuclei of airway epithelial and endothelial cells; when tissue is damaged by allergens, viruses, or mechanical stress, IL-33 is passively released from ruptured cells and triggers immediate type 2 immune activation sits at the very top of the type 2 inflammatory cascade that drives asthma, allergic rhinitis, and atopic sensitization. The IL33 gene on chromosome 9p24.1 is one of the most replicated asthma susceptibility loci in human genetics, and variants at this locus reliably associate with altered IL-33 expression levels in bronchial epithelium, plasma IL-33 protein concentration, and lifetime asthma risk. rs12551256 is an intronic variant within IL33 at GRCh38 chr9:6,231,239. The G allele was negatively associated with asthma in a 1,223-person Brazilian cohort (OR 0.71, P=0.017), suggesting it may sit within or near a regulatory element that modulates IL-33 expression or splicing efficiency.

The Mechanism

After tissue damage, IL-33 is released from the nucleus and binds its receptor complex ST2/IL-1RAcP on mast cells, basophils, and group 2 innate lymphoid cells²² group 2 innate lymphoid cells
ILC2s are innate immune cells that respond to epithelial alarmins (IL-33, IL-25, TSLP) without requiring antigen presentation; they are the dominant early source of IL-5 and IL-13 that drives eosinophilic airway inflammation. Binding activates MyD88→TRAF6→NF-κB and MAPK cascades, causing ILC2s and mast cells to flood the airway with IL-5 (driving eosinophilia), IL-13 (driving mucus and bronchospasm), and IL-9 (driving further mast cell activation). Environmental allergen proteases amplify this loop by cleaving full-length IL-33 into shorter, hyper-potent active forms. Variants that reduce IL-33 output from epithelial cells — whether through altered splicing efficiency, disrupted enhancer elements, or other intronic regulatory effects — blunt this entire cascade upstream of every cytokine downstream of IL-33.

The fine-mapping study at the IL33 locus³³ fine-mapping study at the IL33 locus
Aneas et al. Nature Communications 2021; identified a 5 kb enhancer-blocking element within the GWAS-defined 41 kb LD block that loops to the IL33 promoter; risk alleles rs1888909-T and rs992969-A increase bronchial epithelial IL33 mRNA and plasma IL-33 protein established that the IL33 asthma locus is an expression quantitative trait locus (eQTL) in airway epithelium, not in bulk lung tissue — meaning that the locus specifically tunes how much IL-33 is produced in the epithelial cells most exposed to inhaled triggers. rs12551256 at chr9:6,231,239 lies within the gene body of IL33, approximately 16 kb downstream of rs992969, and may mark an independent or correlated regulatory element within this same eQTL region.

The Evidence

The primary evidence for rs12551256 comes from a Brazilian case-control study⁴⁴ Brazilian case-control study
Queiroz et al., Int J Immunogenet 2017; 1,223 subjects genotyped on Illumina 2.5 Human Omni BeadChip; analyses adjusted for sex, age, helminth infection, and ancestry markers in a mixed European/African admixed population. The G allele was negatively associated with asthma (OR 0.71, 95% CI 0.53–0.94, P=0.017), a ~29% reduction in odds in heterozygotes and a larger expected reduction in GG homozygotes under an additive model. The effect size is modest and has not yet been independently replicated for this specific rsid in other cohorts — hence an evidence level of emerging.

The biological plausibility of a protective intronic variant at the IL33 locus is strongly supported by parallel human genetic evidence. The rare IL33 splice acceptor variant rs146597587-C⁵⁵ rare IL33 splice acceptor variant rs146597587-C
Zhu et al. PLoS Genet 2017; 103,104 participants for eosinophil analysis; 6,465 asthma cases vs 302,977 controls; rs146597587-C heterozygotes have ~40% lower total IL33 mRNA and a strongly protective effect on asthma risk (OR 0.47) and blood eosinophil counts (β=-0.21 SD, P=2.5×10⁻¹⁶) shows that even partial reduction in IL-33 availability provides robust protection against asthma. The clinical importance of the IL-33 pathway is confirmed by a phase 2 trial of itepekimab⁶⁶ a phase 2 trial of itepekimab
Wechsler et al. NEJM 2021; itepekimab (anti-IL-33 mAb, 300 mg SC every 2 weeks) vs placebo in moderate-to-severe asthma; loss-of-control events 22% vs 41%, OR 0.42, P=0.02, an anti-IL-33 monoclonal antibody, which achieved a 46% relative reduction in asthma loss-of-control events.

Practical Implications

Carriers of the G allele may have modestly lower IL-33 signalling capacity in their airway epithelium, which could translate to lower type 2 airway inflammation burden over a lifetime of allergen exposure. For carriers of AA (no G copies), the absence of this potential dampening variant — combined with other IL33 risk alleles at nearby positions — is a signal for proactive airway management. Practical steps include monitoring expiratory flow before symptoms develop and identifying specific aeroallergen triggers that activate airway epithelial IL-33 release (house dust mite proteases, cockroach allergens, tobacco smoke).

Interactions

rs12551256 lies within the IL33 gene body, approximately 16 kb downstream of the main asthma GWAS signal rs992969 and in the same genomic region as the cluster of IL33 eQTL variants. The degree of linkage disequilibrium between rs12551256 and nearby risk variants (rs992969, rs1888909) is not fully defined, particularly in non-European populations. In the Brazilian study population, LD patterns reflect the admixed European/African ancestry structure of the cohort.

rs146597587 (IL33 splice acceptor LOF variant) and rs992969 (IL33 upstream regulatory variant increasing IL33 expression) are the best-characterized IL33 variants in the platform. Carriers of rs12551256-GG with concurrent rs992969-GG (low-risk configuration at both loci) would represent the IL33 haplotype with the most consistent evidence for dampened IL-33-driven airway inflammation.

The receptor-side variant rs1420101 (IL1RL1/ST2) shapes how cells respond to whatever IL-33 is secreted — individuals with rs12551256-G (lower IL-33 production) and rs1420101 variants affecting sST2 decoy receptor levels have a dual dampening effect on the IL-33 → ST2 signalling axis.

Heme oxygenase 2 (HMOX2) is the constitutive enzyme responsible for breaking down free heme in the brain. Unlike its inducible sibling HMOX1, HMOX2 is always switched on — particularly in cerebral blood vessels, neurons, and astrocytes — producing three products at baseline: biliverdin¹¹ biliverdin
converted rapidly to the antioxidant bilirubin by biliverdin reductase, iron, and carbon monoxide (CO)²² carbon monoxide (CO)
a gasotransmitter: a small molecule gas with defined signalling functions in cells, analogous to nitric oxide. That constitutive CO is not merely a metabolic byproduct — it is an active vasosignalling molecule that sets the baseline tone of cerebral arterioles and interacts continuously with the nitric oxide (NO) system.

rs12598836 is an intronic variant within HMOX2 on chromosome 16p13.3. The G allele (the GRCh38 reference) is the migraine risk allele. It is carried at approximately 30% frequency in Europeans but 80% in Africans, making it one of the more population-stratified migraine risk variants identified to date.

The Mechanism

CO produced by HO-2 acts as a tonic vasoregulator³³ tonic vasoregulator
a continuous background signal that holds vascular tone within a narrow physiological range, distinct from acute vasoactive responses in cerebral microvessels. It competes directly with nitric oxide synthase (NOS): CO inhibits NOS by binding to the enzyme's heme prosthetic group, reducing NO output. When HO-2 activity is experimentally blocked, cerebral arterioles dilate — an effect reversed by adding CO back or blocking NOS. This CO-NO balance is precisely the type of vascular regulation relevant to migraine-with-aura pathophysiology.

Cortical spreading depression (CSD)⁴⁴ Cortical spreading depression (CSD)
the electrophysiological wave of neuronal depolarisation and suppression that underlies migraine aura, propagating at 3–5 mm/minute across the cortex alters cerebral blood flow in a characteristic triphasic pattern — initial hyperaemia, then oligaemia, then sustained hypoperfusion. The HMOX2/CO system, by setting baseline cerebrovascular tone and interacting with NO, is positioned mechanistically at exactly this interface between neurovascular coupling and aura. The rs12598836 G allele presumably tags a regulatory change in HMOX2 expression or splicing that shifts this CO-NO balance in a direction that lowers the threshold for CSD initiation or sustains the oligaemic phase that produces aura symptoms.

The Evidence

The primary evidence comes from Hautakangas et al. 2022⁵⁵ Hautakangas et al. 2022
Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles. Nature Genetics, the largest migraine GWAS conducted to date. Among 123 genome-wide significant loci, the HMOX2 locus (rs12598836-G) was one of only three variants with subtype-specific effects exclusive to migraine with aura (14,624 MA cases vs 703,852 controls). The overall migraine odds ratio per G allele is modest — 1.038 (p = 2×10⁻¹⁰) — but the specificity for the MA subtype implicates an aura mechanism rather than the shared migraine headache pathway.

The mechanistic case rests on dedicated HO-2 neurophysiology research. Parfenova and Leffler 2008⁶⁶ Parfenova and Leffler 2008
Cerebroprotective functions of HO-2. Antioxidants & Redox Signaling documented that HO-2 maintains cerebral blood flow during seizures and hypoxia through rapid CO production — without requiring new enzyme synthesis. Ishikawa et al. 2005⁷⁷ Ishikawa et al. 2005
Microcirculation showed that HO-2-derived CO tonically antagonises NO-mediated vasodilation in rat cerebral arterioles, establishing CO from this enzyme as a moment-to-moment cerebrovascular regulator. The link to CSD is supported by Nimura et al. 1996⁸⁸ Nimura et al. 1996
Journal of Cerebral Blood Flow and Metabolism, who showed that prolonged spreading depression induces HO-1 in cortical glia via AP-1 activation — the heme oxygenase pathway responds to and is activated by CSD waves.

The evidence level for the GWAS association is moderate: the study is large and well-powered, but the HMOX2 subtype-specific finding has not yet been independently replicated in a separate MA-specific meta-analysis. The overall migraine association (p = 2×10⁻¹⁰) is genome-wide significant, but the MA-specific effect merits further confirmation.

Practical Actions

For G allele carriers, the modestly elevated migraine-with-aura susceptibility points to the importance of managing triggers that destabilise neurovascular coupling — particularly those that alter the CO-NO balance acutely. The G allele's effect size is small (OR 1.038), meaning it is one of many genetic contributors to MA risk rather than a dominant determinant. For GG homozygotes with diagnosed MA, discussing vasoconstrictor triptans (which target serotonin 5-HT1B/D receptors on cerebral vessels and are the most effective acute MA treatments) with a neurologist is appropriate given the cerebrovascular mechanism involved.

Interactions

The three MA-specific loci identified in Hautakangas 2022 — HMOX2, CACNA1A, and MPPED2 — are worth considering together. CACNA1A encodes the voltage-gated calcium channel P/Q subunit, variants in which cause familial hemiplegic migraine; calcium channel dysregulation lowers the CSD threshold independently of the vascular mechanism. HMOX2 and CACNA1A likely act through distinct pathways (neurovascular vs neuronal excitability), so co-inheritance of risk variants in both genes could have an additive effect on MA susceptibility.

rs10166942 (TRPM8) is an established migraine risk SNP in the same neurology-cognition category; TRPM8 mediates cold-triggered pain sensitivity and cerebrovascular responses, representing a distinct pathway to migraine susceptibility from the HO-2/CO axis.

LPIN1 encodes lipin-1, a dual-function protein at the heart of lipid metabolism. In the cytoplasm, lipin-1 acts as a phosphatidic acid phosphohydrolase¹¹ phosphatidic acid phosphohydrolase
A Mg²⁺-dependent enzyme that converts phosphatidic acid to diacylglycerol, the branch-point metabolite required for both triglyceride storage and phospholipid membrane synthesis. In the nucleus, lipin-1 switches roles entirely: it acts as a transcriptional co-activator of PGC-1α and PPARα, driving genes for fatty acid oxidation and mitochondrial metabolism while suppressing lipogenic gene expression. This makes LPIN1 a physiological gatekeeper that normally keeps the liver from accumulating excess fat during periods of caloric load.

The rs13412852 C>T variant sits within an intron of LPIN1 on chromosome 2 (chr2:11,774,815, GRCh38) and does not alter the protein sequence. Its functional impact is not established at the molecular level, but population studies have uncovered context-dependent associations with liver fat, triglycerides, and disease progression — associations that differ strikingly between children and adults.

The Mechanism

LPIN1 is on the plus strand of chromosome 2. The rs13412852 C allele is the GRCh38 reference allele, present on approximately 75% of chromosomes globally. The T allele (minor allele, ~25% globally) may alter intronic regulatory elements — such as splicing enhancers, microRNA binding sites in the pre-mRNA, or chromatin accessibility signals — though no specific molecular mechanism has been established.

The most clinically distinctive feature of this variant is a gene-environment interaction²² gene-environment interaction
A pattern where a genetic variant's effect on disease depends on an environmental exposure; here, physical activity level acts as the environmental modifier. In adults who are physically active, the T allele appears to have a modest or even protective metabolic effect. In adults with sedentary behavior, T-carrier status substantially amplifies the risk of metabolic dysfunction-associated steatotic liver disease (MASLD).

The Evidence

Pediatric NAFLD (protective signal): A study by Valenti et al. 2012³³ Valenti et al. 2012
Valenti L et al. LPIN1 rs13412852 polymorphism in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2012 examined 142 children with biopsy-proven NAFLD and 337 healthy controls. The TT genotype was under-represented among pediatric NAFLD cases (7% vs 14% in controls; OR 0.58, 95% CI 0.35–0.91). Children with the TT genotype had significantly less severe liver damage (NAFLD activity score, P=0.026) and a lower prevalence of liver fibrosis (P=0.012, adjusted OR 0.29, 95% CI 0.11–0.66). The same group found TT homozygosity associated with lower triglycerides in both patients and healthy controls.

These findings fed into a 4-polymorphism pediatric NASH risk score⁴⁴ 4-polymorphism pediatric NASH risk score
Nobili V et al. 2014 — combining PNPLA3 rs738409, SOD2 rs4880, KLF6 rs3750861, and LPIN1 rs13412852 to predict NASH in obese children; AUC 0.75 for the genetic score, 0.80 for the combined clinical-genetic model.

Adult MASLD (risk signal with sedentary behavior): A 2026 Italian cohort study by Franco et al.⁵⁵ Franco et al.
Franco I et al. The Interplay of Genetics and Lifestyle in MASLD: Focus on LPIN1 rs13412852 and Sedentary Behaviour. Int J Mol Sci. 2026 genotyped 394 adults and found that CT/TT genotype was associated with MASLD independently (OR 1.80, 95% CI 1.06–3.05, P=0.03). Sedentary behavior was also an independent risk factor (OR 1.72, P <0.05). The critical finding was their interaction: individuals with both moderate-to-severe sedentary behavior and the CT/TT genotype had an MASLD risk of OR 2.99 (95% CI 1.39–6.45, P=0.005) — roughly tripling risk compared to physically active CC individuals.

UK meta-analysis (minimal effect on fasting metabolites): A meta-analysis of 8,504 UK subjects found only a nominal association between rs13412852 T allele and lower BMI (P=0.042) and slightly lower fasting insulin, with no significant association with insulin resistance overall. The authors concluded that common LPIN1 variation has no major effect on metabolic traits in isolation.

The evidence level remains emerging: the adult-sedentary interaction is a compelling finding from a single moderate-sized cohort (n=394) requiring replication. The pediatric protection signal, though biologically plausible, also requires larger studies.

Practical Actions

The most actionable implication of rs13412852 is that T-carriers should be particularly vigilant about physical inactivity. The sedentary-genotype interaction suggests that the T allele heightens the liver's vulnerability to the metabolic consequences of reduced physical activity. This is genotype- specific advice: the roughly 3-fold risk amplification in sedentary T-carriers is meaningfully larger than the sedentary risk seen in CC individuals alone.

T-carriers with existing sedentary work or lifestyle patterns should prioritize breaking sitting time with structured movement, and should monitor hepatic fat markers (liver enzymes, hepatic ultrasound) if other risk factors for MASLD are present (obesity, insulin resistance, dyslipidemia).

Interactions

This variant does not have documented gene-gene interactions, but it is part of a validated 4-variant pediatric NASH risk score alongside PNPLA3 rs738409 (I148M), SOD2 rs4880, and KLF6 rs3750861. Individuals who carry the LPIN1 T allele alongside the PNPLA3 GG risk genotype face the highest combined pediatric NASH risk in that score. The relationship between LPIN1 lipin-1 and the PPARG/PGC-1α transcriptional axis also suggests that PPARG variants (such as the Pro12Ala polymorphism) may modulate how strongly LPIN1 expression is regulated — though this gene-gene interaction has not been directly tested for rs13412852.